PDF Presentation: d-lysergic_acid_diethylamide_lsd_.pdf

PowerPoint Presentation: d-lysergic_acid_diethylamide_lsd_.pptx

“Will Be Done After Wiki is Completed - Short Summary of Everything”

Your Brain on LSD and Acid:

• Bill Gates (Co-founder of Microsoft): In a 1994 Playboy interview he mentioned his experiences with LSD in from mid-20’s. He described them as mind-boggling experiences that helped him understand who he really was (Smith, 2015).

• Steve Jobs (Co-Founder of Apple): Stated that his LSD usage in late teens was one of the 2 or 3 most important things he ever did in his life. He credits his outside-the-box perspective to LSD. He claims it helped him think of the world in a different way (Smith, 2015).

• The Beatles (Band): In a 2004 interview Paul McCartney stated that their songs “Day Tripper” and “Lucy in the Sky with Diamonds” are about LSD and that the band wrote several of their songs while on LSD or soon after taking LSD including multiple number one hits (Smith, 2015).

• Francis Crick (Co-Discoverer of the Structure of the DNA Molecule): In a 2004 interview Francis Crick claimed himself as well as many researchers at Cambridge would take LSD in small amounts to aid in their thinking. Crick also stated he would be unsure if the discovery of the structure of the DNA would have happened if he did not use LSD (Smith, 2015).

• Katy Mullis (Refined the Polymerase Chain Reaction Technique (PCR)): A year after winning the Nobel Prize in Chemistry in 1993 for his biochemical breakthrough in refining the PCR he admitted to binging LSD in the 60’s and 70’s. He went to proclaim that LSD was far more important to his accomplishments than any courses he ever took. He went as far as to claim that his entire legacy probably depended LSD (Smith, 2015).

• Doc Ellis (Former MLB Pitcher): Former Major League pitcher for the Pittsburgh Pirates, once took LCD forgetting he was the planned starting pitcher against the San Diego Padres. He ended up throwing a no-hitter during the game while still under the effects of LCD. He claimed to have not seen any of the batters and was simply trying his best to throw in right direction on the June 12, 1970 night (Smith, 2015).

Others: (Smith, 2015)

• Anthony Bourdain (Chef)
• Phil Jackson (Former NBA Coach/Player)
• Jack Nicholson (Actor)
• Dr. Andrew Weil (American Author and Physician)

LSD is classified as a psychedelic drug which means its primary function is to alter cognition and perception as well as many other psychological issues (Blachford & Krapp, 2010). LSD is also considered an hallucinogenic which means LSD causes hallucinations which is when people see, hear, smell, taste or feel things that do not exist in reality but do so in their own minds (Blachford & Krapp, 2010). LSD has been known to put individuals in a dream like stage where they see rather abstract images. LSD is at this point in time strictly a recreational drug and have no purpose outside of producing an altered state of consciousness by modifying the perceptions, feelings, and emotions all for pleasure (Blachford & Krapp, 2010). LSD's classification as recreational drug may not hold true very long with research going on about potentially having LSD used as a treatment for a variety of causes. LSD has well over 40 street names including popular names such as Acid, California Sunshine, Loony Toons, Lucy and Superman (Blachford & Krapp, 2010). Unlike popular recreational drugs such as Cocaine and Heroin, LSD is a tolerance building drug. In order to produce the same effects, increased quantities of LSD is required after each usage due to the brain obtaining tolerance to the drug (Blachford & Krapp, 2010).

Figure 1 Source: https://www.justice.gov/archive/ndic/pubs11/12620/odd.htm

Figure 1: The percentages of LSD usage in different groups between 1999 and 2004.

People largest demographic group to use LSD are middle/upper-middle class whites (Krebs & Johansen, 2013). Men use LSD more often than women which is a common with all risk taking behaviors including any drug use (Krebs & Johansen, 2013). LSD is rarely taken by individuals above the age of 28. It is implied that the younger population are willing to have a desire for psychological experiences and to go on such psychological trips (Blachford & Krapp, 2010). As seen in figure 1 the usage of LSD has decreased across all age groups as individuals are afraid of the potential brain damage that can occur which is usually is usually exaggerated as well governments limiting its distribution through strict laws (Blachford & Krapp, 2010). Unlike most recreational drugs most people only take LSD once. In fact about 89% of LSD users only take it once and never again. This occurs simply because LSD is not physically addictive (Krebs & Johansen, 2013).

Figure 2 Source: http://www.themindcentre.com.au/microdosing-lsd-psychedelic-drugs-treatment-future/

Figure 2: The structures of Serotonin HT-5 and LSD

LSD is a tasteless, odorless and colorless crystal in its natural state (Krebs & Johansen, 2013).. It is virtually impossible to identify it without actually be told or having not extracted yourself. For recreation use LSD can be taken in a variety of ways most commonly by a dissolving stamp on the tongue (Krebs & Johansen, 2013).. It can however also be admin-started as a liquid and gas through the mouth, nose, eyes and anus. LSD is water soluble, because this compound has the amine groups (Krebs & Johansen, 2013). The water solubility is enhanced by the hydrogen bonding involving the lone pairs of the amine group (Li & Wang, 1998). Also, this compound can decomposes in light and high temperature. It decomposes in the light condition, because UV light can induce the C-9,10 double bond of LSD undergoes photocatalytic hydration (Li & Wang, 1998). The LSD is molecule is considered unstable and most be stored and cared for appropriately or risk damage or ineffective drug (Li & Wang, 1998). The key biochemical property of LSD is that its structure is very similar to that of serotonin which can be noticed in figure 2. This allows LSD molecules to behave and react in a very similar manner as serotonin in the body such as binding to the same receptors. The additional fictional group son LSD allow the molecule to do the role of serotonin even better than serotonin itself. Such benefits includes binding longer to the receptors and avoiding degradation longer (Li & Wang, 1998).

Lysergic Acid Diethylamide (LSD) interacts with receptors in the brain known as 5-HT receptors (also known as 5-hydroxytryptamine receptors or serotonin receptors) (Schiff, 2006). Interaction with these receptors results in an agonist (physiological response occurs) or partial antagonist (inhibited physiological responses) on serotonin activity (Schiff, 2006). 5-HT1A and 5-HT1B receptors are the two presynaptic receptors involved in this interaction while 5-HT2 receptors are the postsynaptic receptors (Schiff, 2006). LSD like many other hallucinogens promote the release of glutamate in thalamocortical terminals (Schiff, 2006). Having the release of this neurotransmitter creates a dissociation between sensory relay centers and cortical output (Schiff, 2006). Other than these steps, not much else is known about the mechanism of action for LSD. Figure 3 demonstrates the effectiveness of LSD at mimicking the role of serotonin and the cascade of events that occur post binding that researchers believe occurs (Schiff, 2006).

Figure 3 Source: http://flipper.diff.org/apprulesitems/items/4051

Figure 3: Binding of LSD vs. Serotonin to 5-HT receptors and the potential post cascade.

Brain networks dealing with vision, attention, movement and hearing become far more connected, this creates what looks like a more connected, more unified brain in an individual (Carhart-Harris et al., 2016). Other networks in the brain are broken down/disintegrated, leading to the activity to become more entropic, meaning that more of a state of disorder is created. This comes about due to these networks becoming separated (Carhart-Harris et al., 2016). A scan of a user who took LSD showed that there was a loss of connections between part of the brain called the parahippocampus and another region called the retrosplenial cortex (Carhart-Harris et al., 2016). The retrosplenial complex is on the posterior side of the brain and involves spatial navigation of the body. On the other hand, the parahippocampal region of the brain involves memory retrieval and encoding and is the area that surrounds the hippocampus. An individual will experience a feeling of “ego dissolution”, a feeling that describes an individual who feels less of being a singular entity and has now become one that is blended with the environment or others around them (Cormier, 2016). In other words, this means that an individuals self-identity is becoming lost. Lysergic Acid Diethylamide is not a physically addictive drug, however, the drug may become addicting psychologically to the individual. The user may enjoy the trips that they may have and become addicted to feeling and experiencing these hallucinations (Das et al., 2016).

A dosage of 1–3 µg/kg body weight is enough to produce moderate, behavioral effects (Das, Barnwal, Ramasamy, Sen, & Mondal, 2016). LSD’s effects can be observed within 30-60 minutes of ingesting and can peak over 1-6 hours and dissipates in 8-12 hours (NIDA, 2016). Acute toxicity can upset the gastrointestinal system and cause chills while also stimulating the sympathetic nervous system resulting in hypothermia, palpitation, hypertension, hyperglycemia, tachycardia, and panic (NIDA, 2016; Das et al., 2016). They have dramatic changes in their feelings and sensations such as rapidly changing emotions (NIDA, 2009). LSD can also affect the motor system leading to increased activity of monosynaptic reflexes which result in muscle incoordination, which is considered a symptom of religious ecstasy where the worshipper (user) is displaying the love of God (Aghajanian & Marek, 1999; Das et al., 2016).

Large doses of LSD can cause delusions and visual hallucinations with an altered sense of time and self along with cross-over of senses such as hearing colours and seeing sounds (NIDA, 2009). In some cases, users experience terrifying thoughts and feelings of despair, insanity, death and losing control (NIDA, 2009). Some other mental effects include an impaired perception of depth, time, size, shape of objects, movements, touch, body image as well as an artificial sense of certainty or euphoria(Das et al., 2016; Liester, 2014). They may also experience sudden or delayed flashbacks which may persist, causing distress, impairment in everyday occupational and social functioning (NIDA, 2009). Chronic effects may include flashbacks and worsening latent mental disorders such as schizophrenia and severe depression (Das et al, 2016; NIDA, 2016).

Figure 4 Source: https://www.recovery.org/topics/lsd-facts/

Figure 4: Some of the potential side-effects of LSD usage.

An overdose of LSD leads to “bad trips” which include intense anxiety, combat-behavior, panic, confusion and a simple touch and normal sensations seem strange and bizarre(Das et al, 2016; NIDA, 2016). There are also adverse health effects associated with ingesting LSD and depending on the dosage, it may result in dilation of pupils, high body temperature, increased heart rate and blood pressure as well as lots of sweating, decreased appetite, tremors and dry mouth (NIDA, 2009).

LSD does not cause overpowering drug-seeking behaviour and it is not classified as an addictive drug however, by producing tolerance to LSD, frequent users must intake higher dosage to achieve same intoxication effects (NIDA, 2016). Although there is no withdrawal syndrome or physical dependence on LSD, there is low psychological dependence, but no deaths have been reported entirely due to LSD use (NIDA, 2016).

LSD is a powerful mood-changing, psychedelic agent which is mainly used for recreational and spiritual purposes and since it is sold on the illicit market, it is not used in medical treatments although scientists now are speculating its usefulness as a therapeutic agent (Das et al, 2016; NIDA, 2016). It can also be used as a component of psychedelic peak therapy for alcohol and drug dependence in terminally ill patients (Das et al., 2016). Some suggest that these psychedelic drugs have great potential for research in psychiatry and psychology while others suggest the usefulness of its effects in psychotherapy (Das et al., 2016).

Hoffman, the inventor of LSD, stated that through this drug allowed access to the spiritual world allowing the user to feel as if their ‘eyes have been cleansed’ and they can ‘see the world as new’ (Das et al, 2016; Grob, 2002; Ruck et al, 1979). LSD also increases user’s appreciation of the surrounding environment and boosts their creativity, while raising their awareness to mystical and religious experiences (Das et al., 2016; Passie, Halpern, Stichtenoth, Emrich, &Hintzen, 2008).

LSD was once legally available for clinical use in experimental treatments until late 1960s (Das et al, 2016; Grinspoon L &Bakalar J, 1997). In the early 1960s, LSD along with counseling reduced anxiety, depression and pain in patients with advanced cancer (Das et al., 2016; Kast & Collins, 1964).They reported the use of LSD; in ventilation of emotions in schizophrenics, as therapy for obsessional neurosis and anxiety and psychoanalytic therapy(Das et al., 2016). Clinicians also explored its therapeutic use in anxiety disorders, addictions, obsessive-compulsive disorders and sever depression among other conditions (Das et al., 2016).However, due to the adverse side effects including harmful behaviour, the Hallucinogenic Drug Regulations was implemented in 1967 to limit the use of such drugs only by qualified practitioners(Das et al., 2016).

Some interesting therapeutic uses of LSD suggest that it can act as an antianxiety agent, enhance; user’s creativity, suggestibility and performance (Das et al., 2016). The use of hallucinogenic agents to enhance creativity in artists began in the 1960s and it could alter the sensory modalities of the user, change emotions and expanded their sense of thought, identity and creativity (Das et al., 2016; Dobkin de Rios &Janiger O, 2003). If LSD is ingested as a controlled, therapeutic agent in a proper setting, its mystical experience can allow the patient to develop a deeper level of self understanding and self-acceptance but the therapist must have an in-depth knowledge of the patient’s psychopathology (Das et al., 2016).

LSD was studied and researched heavily in the 1950’s and 1960’s (Morgan et al., 2017). During this time frame there was the release of more than 1000 academic papers and the publication of several dozen books all on the use of LSD for therapeutic purposes particularly in the field of psychotherapeutics (Morgan et al., 2017). In the 1960’s cultural and government backlash lead to the classification of LSD as a schedule I drug which resulted in the abandonment of research in both universities and commercial laboratories (Morgan et al., 2017). Laws limiting research on LSD remained strict until the late 90’s and experimentation/testing in humans was not allowed until 2009 which has since revitalized LSD research (Nichols, 2016). All previous research from the 50’s-60’s is considered invalid due to the lack of scientific process being used, small sample sizes, lack of technology and biases on researchers who either heavily sided with or were against LSD use (Nichols, 2016). Several of the studies done decades ago are now being re-done insuring accurate results in additional to new studies looking at the effects of LCD on the human brain and how it can help with a variety of human troubles varying from physical, to psychological and emotional (Morgan et al., 2017.

LSD Treatment for Alcoholism:

A recent meta-analysis combined the results of 6 randomised controlled trails which assessed the efficacy of LSD as potential treatment for alcoholism (Krebs & Johansen, 2012). The total of 536 participants who were all administrated for alcohol abuse was given either up to 50 micro grams of LCD (significantly less than the normal dosage) or a placebo (control group) on a regular schedule (Krebs & Johansen, 2012). During the testing timeframe all participants would also undergo normal alcohol abuse therapy. All participants would be regularly checked on and would self-report with milestone checks for short-term (3 months), medium-term (6 months) and in the long-term (12 months). At the 3 month mark 59% of active treatment participants showed reliable improvement, meaning they were consuming less alcohol and showed improved results in therapy (Krebs & Johansen, 2012). This was significantly higher than the control groups in which case only 39% demonstrated the same improvement (Krebs & Johansen, 2012). At the 6 month mark this difference drops but is still very much present. However, by the long-term 12 month check the benefits seen before were not maintained and most participants regained their old habits or plateaued without full recovery (Krebs & Johansen, 2012).

LSD Treatment for Opioid and Other Drug Addictions:

The recent tests were designed similar to the studies done with participants with alcohol addictions were done with those with opioid addictions as well as other drug addictions such as cocaine and heroin (Pisano et al., 2017). The results of such tests were not as positive as those done with alcoholism (Pisano et al., 2017) . In the short term those given LSD demonstrated a significant improvement compared to control groups in the same study but the effectiveness dropped considerably well before the 6 month mid-term point (Pisano et al., 2017).

New Technology and Learning Effects on Brain Mechanisms:

In the last few years studies have started on the acute effects of LSD on brain mechanisms in healthy individuals (Carhart-Harris et al., 2016). These individuals have no form of mental illness, no substance abuse issues and are of moderate intelligence (Carhart-Harris et al., 2016). Society is more capable of studying such mechanisms due to the betterment of technology and better research skills (Carhart-Harris et al., 2016). In the 60’s and 70’s researchers were limited to electroencephalography (EEG) but now have the ability to use emission tomography (PET) and functional magnetic resonance imaging (fMRI) which are both considered more effective (Carhart-Harris et al., 2016). Many studies are currently using such methods to understand the true effects of LSD on different parts of the brain in order to be able to better find potential suitable uses for LSD (Carhart-Harris et al., 2016). One such study used a comprehensive placebo-controlled neuroimaging design to look at which parts of are activated beyond normal levels. 20 healthy patients attended 2 scanning days, 2 weeks apart in a balanced-order, within-subject design for both LSD and placebo (Carhart-Harris et al., 2016). Drug/placebo was administrated to all participants. During the sessions both an fMRI and Magnetoencephalography (MEG) were done multiple times before drug activation, while the drug is working as well as well after the effects of the drug have worn off. While the LSD was in effect participants would note down eyes-closed visual hallucinations and the complexity of such visuals (Carhart-Harris et al., 2016). When looking at the end results there was significant difference in cerebral blood flow (CBF) with certain portion of the brain (Carhart-Harris et al., 2016). Greater CBF was observed under LSD in the visual cortex compared to the placebo group. The magnitude of such increases correlated positively with participants ratings on the complex imagery during their altered state of consciousness (ASC) while under LSD (Carhart-Harris et al., 2016). This would indicate that the visual cortex has a key role in the effects of LSD and that LSD has the capabilities of upregulated its activity. Similar tests have been done all a multitude of other brain parts (Carhart-Harris et al., 2016).

Source of Figure 5: http://www.pnas.org/content/113/17/4853.full

Figure 5: An image of the produced results from Carhart-Harris et al. 2016 experiment looking at CBF in the brain and the visual cortex.

LSD Studies with Optimism/Openness/ Creativity/Imagination:

As recent as 2016 studies have occurred looking at the potential impact of LSD on increasing human optimism, openness, creativity and imagination after the use of LSD (Lebdev et al., 2016). Throughout history many celebrities, inventors and artists have claimed that using LSD helped in their career success. Researchers today want to know if LSD can truly increase brain functions that would led to such success (Lebdev et al., 2016). Testing such factors is often very difficult due to not have a specific scale to measure them with and due to self-report of the participants (Lebdev et al., 2016). However, the testing that has been done have garnered rather positive positives. In one study of note 20 random healthy volunteers received 75 micro-grams of LSD and were asked to come back in 2 weeks later (Lebdev et al., 2016). After, the two weeks had passed all 20 volunteers scored higher on optimism, openness, creativity and imagination tests than they did before taking the LSD. It is also of note that such results hold true even with micro-dosing in which only 1/10 of the usual dosage is required (Lebdev et al., 2016). Although such results cannot be taken as scientific fact it has opened the door to further tests as well as further research of LSD as a potential anxiety medication or pain suppressor (Lebdev et al., 2016).

Another interesting experiment looking at the effects of LSD on such traits was done with a single artist (Savage & McCabe, 1973). The artist was given recreational amounts of LSD and was told to draw the researchers ever 10-15 minutes exactly as he saw him. The results of this experiment can be seen in Figure 6 (Savage & McCabe, 1973).

Figure 6 Source: http://www.openculture.com/2013/10/artist-draws-nine-portraits-on-lsd-during-1950s-research-experiment.html

Figure 6: The images drawn by the artist (participant) in the 1973 experiment.

LSD Treatment for End-of-Life Anxiety/Pain:

In Switzerland there is research ongoing since 2008 that is looking into using LSD to alleviate anxiety for patients who are terminally ill with cancer in order to cope with their impending deaths (Gasser et al., 2014). The preliminary results of the study are promising and many in the field are excited about the next steps of the treatment. One study found that 12 months after LCD treatment, patients reported a significant reduction in anxiety and a rise in their quality of life with many of the patients stating the treatment helped them change their habits, see the world in a another view as well coming to the realization that death is a part of life (Gasser et al., 2014). Another test looking at the short-term impact of LCD treatments compared the heart rates and blood pressures post LSD treatment between experimental and placebo groups as such variables when abnormally high are strong indicators of anxiety/stress (Gasser et al., 2014). In this group of 12, the 8 experimental participants had significantly lower heart rates and blood pressures than the 4 in the placebo groups immediately after in taking the treatment as well as 4 hours and 8 hours later (Gasser et al., 2014). Through the several studies no negative effects have been reported in the patients. Such results have opened the door for researchers to test LSD with those who are depressed, have phobias, OCD and other anxiety driven psychological issues (Gasser et al., 2014).

Figure 7 Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086777/

Figure 7: HR and BP results results of the Gasser et al., 2014 experiment with terminally ill cancer patients.

LSD Treatment for Cluster Headaches:

Cluster headache is a neurological disorder characterized by recurring and frequent severe headaches (Passie et al., 2008). These occur on only one side of the head and occur for the most part around the eye (Passie et al., 2008). Only 0.1% of the population experience these in their lifetime (Passie et al., 2008). They are described as feeling worse than natural childbirth or amputation without anesthetics (Passie et al., 2008). There is no treatment for such headaches and using normal pain-killers have caused the pains to increase in severity. Case-reports have indicated that LSD can reduce cluster pain as well as interrupt the cluster-headache cycle preventing future headaches from occurring (Passie et al., 2008). The mechanism of how cluster headaches come about is not well known and thus the effects LSD have on them are also not known but a correlation does seem to exist (Passie et al., 2008). A 2006 study by researchers looked at 53 cluster headache sufferers who were treated with LSD and a majority of the participants reported beneficial effects (Passie et al., 2008). It seems as though for LSD to have a beneficial effect sub-psychedelic dosages are needed. Currently a dose-response study testing the effectiveness of LSD is being conducted (Passie et al., 2008).

More Information:

MAPS (Multidisciplinary Association for Psychedelic Studies) was founded in 1986 (MAPS, 2017). MAPS is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the use of psychedelics and marijuana safely (MAPS, 2017). This includes LSD. The site is a great way to obtain information of LCD, look into current research/projects, donate, ask questions and a way to keep up with any news regarding the drugs on hand. MAPS does not push for illegal usage of drugs but rather pushes for safe, legal and beneficial use of drugs such as LSD (MAPS, 2017).

LSD Addiction and Abuse Help:

For those using LSD and are abusing its use there are plenty of ways to go about getting help (Hermann, 2016). Most local abuse therapy centres or clinics should cover LSD usage issues and help as much as possible (Hermann, 2016). There are also LSD recovery centers for those in more dire situations. Even though LSD is not addictive many people are unable to stop using LSD and/or are no longer satisfied with life outside LSD (Passie et al., 2008). LSD risks can also occur as a vast majority of users if not under control will start taking far more dangerous drugs or will began experimenting (Passie et al., 2008).. There are also a variety of credible websites that can help someone stop LSD usage by following specific instructions (Hermann, 2016). Example: https://www.recovery.org/topics/quitting-lsd/. LSD rehab can include support groups, behavioral therapy and even family therapy.

In conclusion LSD is a psychedelic that drug alters cognition, perception acts as an hallucinogen(Blachford & Krapp, 2010). LSD usage which peaked in the 1960's has seen a vast decrease in its usage for all age groups (Krebs & Johansen, 2013). The key biochemical property of LSD is that its structure is very similar to that of serotonin which allows it to behave and react in a very similar manner as serotonin such as binding to the same receptors (Li & Wang, 1998). Under LSD a wide range of symptoms and effects occur including some parts of the brain being more connected to other parts becoming less connected(Das et al., 2016). Symptoms vary depending the individual and the amount taken (NIDA, 2016). LSD usages are strictly limited to recreational use but current research such as; LSD Treatment for Alcoholism, LSD Treatment for Opioid and Other Drug Addictions, LSD Studies with Optimism/Openness/ Creativity/Imagination, LSD Treatment for End-of-Life Anxiety/Pain and LSD Treatment for Cluster Headaches have started opening the door for LSD to be used in more important ways. It is important to educate oneself with such drugs as with every positive feature comes many negative ones. MAPS is a great organization to look into in order to obtain such new information (MAPS, 2017). It is still recommended to avoid doing illegal drugs such as LSD to avoid the emotional, physically and economic damages that can occur especially if a state of abuse occurs.

Aghajanian, G. K., & Marek, G. J. (1999). Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release. Brain Research, 825(1–2), 161–171. https://doi.org/10.1016/S0006-8993

Blachford, S. L., & Krapp, K. (2010). LSD (lysergic acid diethylamide). Drugs and Controlled Substances: Information for Students. Retrieved from http://sproxy.glenbrook225.org/login?url=http://link.galegroup.com/apps/doc/CV2645000028/SCIC?u=gotitans&xid=8a0a151

Blewett D., and Chwelos N. (1959). Handbook for the therapeutic use of lysergic acid diethylamide 25 individual and group procedures. Retrieved from https://www.erowid.org/psychoactives/guides/handbook_lsd25.shtml

Carhart-Harris, R.L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K.,…Nutt, D.J. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings Of The National Academy Of Sciences, 113(17), 4853-4858. http://dx.doi.org/10.1073/pnas.1518377113

Cormier, Z. (2016). Brain scans reveal how LSD affects consciousness. Nature, 99(2), 4577-4579. http://dx.doi.org/10.1038/nature.2016.19727

Das, S., Barnwal, P., Ramasamy, A., Sen, S., & Mondal, S. (2016). Lysergic acid diethylamide: a drug of ‘use’? Therapeutic Advances in psychopharmacology, 6(3), 214–228. https://doi.org/10.1177/2045125316640440

Dobkin de Rios M., & Janiger O. (2003). LSD, Spirituality and the Creative Process. Rochester, NY, USA: Park Street Press.

Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., . . . Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513–520. https://doi.org/10.1097/NMD.0000000000000113

Grinspoon L., & Bakalar J. (1997). Psychedelic Drugs Reconsidered. New York, NY, USA: Lindesmith Center.

Hermann, E. (2016). What You Should Know About Quitting LSD. Retrieved from https://www.recovery.org/topics/quitting-lsd/

Kast, E. C., & Collins, V. J. (1964). Study of lysergic acid diethylamide as an alangestic agent. Anesthesia and Analgesia, 43, 285–291. Retrieved from https://insights.ovid.com/pubmed?pmid=14169837

Krebs, T. S. & Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994-1002. https://doi.org/10.1177/0269881112439253   Krebs, T. S., & Johansen, P.O. (2013). Over 30 million psychedelic users in the United States. F1000Research, 2, 98. http://doi.org/10.12688/f1000research.2-98.v1

Liester, M. B. (2014). A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects. Current Drug Abuse Reviews, 7(3), 146–156. https://doi.org/10.2174/1874473708666150107120522

Lebedev, A.V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D.J., . . . Carhart-Harris R.L. (2016) LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 37(9), 3203–3213. https://doi.org/10.1002/hbm.23234

Lewis, R.J. (2007). Hawley's Condensed Chemical Dictionary 15th Edition (pp. 773). New York, NY., John Wiley & Sons, Inc.

Li, Y. Z., McNally, A. J., Wang, H. Y., & Salamone, S. J. (1998). Stability study of LSD under various storage conditions, Journal of Analytical Toxicology, 22(6): 520–525. https://doi.org/10.1093/jat/22.6.520

MAPS (2017). What Is MAPS?. Retrieved from http://www.maps.org/

Morgan C., McAndrew, A., Stevens, T., Nutt, D., & Lawn, W. (2017). Tripping up on addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use. Current Opinion in Behavioral Science, 13, 71-76. https://doi.org/10.1016/j.cobeha.2016.10.009

National Institute on Drug Abuse (NIDA). (2016). Hallucinogens. Retrieved from https://www.drugabuse.gov/publications/drugfacts/hallucinogens%20on%202017

National Institute on Drug Abuse (NIDA). (2009). Hallucinogens: LSD, Peyote, Psilocybin, and PCP. Retrieved from https://www.drugabuse.gov/sites/default/files/hallucinogens09.pdf

Nichols, D.E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355. https://doi.org/10.1124/pr.115.011478

Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: a review. CNS Neuroscience & Therapeutics, 14(4), 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x

Pisano, V.D., Putnam, N.P., Kramer, H.M., Franciotti, K.J., Hapern, J.H., & Holden, S.C. (2017). The association of psychedelic use and opioid use disorders among illicit users in the United States. Journal of Psychopharmacology, 31(5), 606-613. https://doi.org/10.1177/0269881117691453

PubChem. (2017). Lysergide. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/5761

Ruck, C. A., Bigwood, J., Staples, D., Ott, J., & Wasson, R. G. (1979). Entheogens. Journal of Psychedelic Drugs, 11(1–2), 145–146. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/522165

Savage, C., & McCabe, O.L. (1973). Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry, 28, 808-814. https://doi.org/10.1001/archpsyc.1973.01750360040005

Schiff, P. L. (2006). Ergot and its alkaloids. American Journal of Pharmaceutical Education, 70(5), 98. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1637017/

Smith, P. (2015). 7 People Who Say They Owe Their Huge Success to Psychedelics. Retrieved from https://www.alternet.org/drugs/seven-high-achievers-credit-psychedelics-their-success